Jump to content
RemedySpot.com

The emerging role of lenalidomide in the management of lymphoid malignancies

Rate this topic


Recommended Posts

Posted

BlankThe emerging role of lenalidomide in the management of lymphoid

malignancies

1.. Sameer A. Batoo

1.. Department of Medical Oncology and Immunology, Roswell Park Cancer

Institute, Buffalo, NY, USA

1.. Francisco -Ilizaliturri francisco.hernandez@...

1.. Department of Medical Oncology and Immunology, Roswell Park Cancer

Institute, Buffalo, NY, USA

Abstract

Lenalidomide, a novel immunomodulatory drug (IMiD), is a promising therapeutic

strategy for patients with relapsed/refractory chronic lymphocytic leukemia

(CLL) and B-cell lymphomas. Biologically, the mechanisms responsible for

lenalidomide activity are yet to be clearly defined. Based on preclinical models

and early correlative studies conducted in parallel to clinical trials,

lenalidomide has been found to enhance natural killer (NK)- and T-cell activity

against tumor cells, alter the balance of pro- and anti-inflammatory cytokines

in the tumor bed, inhibit angiogenesis, and, to a lesser degree, induce cell

cycle arrest and apoptosis in cancer cells. Together, all of these biological

effects appear to play a role in the activity observed in CLL or lymphoma

patients treated with lenalidomide. Given the effect in NK- and T-cell function,

lenalidomide is an alternative strategy to enhance the antitumor activity of

monoclonal antibodies (mAbs). Clinical responses have been observed in patients

with relapsed/refractory CLL, follicular lymphoma, small lymphocytic lymphoma,

mantle cell lymphoma, and diffuse large B-cell lymphoma (DLBCL) treated with

lenalidomide single agent. The favorable toxicity profile and route of

administration made the use of lenalidomide an attractive therapy for certain

types of patients (i.e. elderly, chemotherapy unfit, etc.). The erratic but

serious incidence of tumor lysis syndrome and/or tumor flare reactions provides

challenges in the incorporation of lenalidomide in the management of previously

untreated CLL or CLL/lymphoma patients with bulky adenopathy. Correlative

studies and/or retrospective analysis of lenalidomide-treated patients had

identified several biomarkers associated with clinical endpoints in CLL (i.e.

changes in tumor necrosis factor alpha [TNF-a] or vascular endothelial growth

factor [VEGF] levels) or DLBCL (non-GCB phenotype) patients, but need to be

validated. Early studies evaluating the efficacy and toxicity of lenalidomide in

combination with rituximab in previously untreated indolent lymphoma are

promising and warrant further study. In addition, the evaluation of lenalidomide

in the maintenance setting or in combination with other target-specific agents

(i.e. proteasome inhibitors) in aggressive lymphomas is being addressed in

ongoing clinical trials. In summary, lenalidomide is emerging as a biologically

active and novel agent in the treatment of B-cell neoplasms. Future

translational and clinical studies will further define the role of lenalidomide

in the management of de novo or relapsed/refractory CLL or B-cell lymphomas and

identify the subset of patients most likely to gain clinical benefit.

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...
×
×
  • Create New...